Bayer to strengthen core life science businesses while significantly enhancing productivity and profitability

Group plans to exit Animal Health business, the Consumer Health brands Coppertone™ and Dr. Scholl’s™, and sell its 60-percent interest in Currenta, a site services provider in Germany / Efficiency and structural measures set to enhance competitiveness and generate annual contributions of 2.6 billion euros as of 2022 including the expected synergies from the Monsanto acquisition / A portion of the contributions to be reinvested in core businesses / Total one-time costs expected at a factor of 1.7 times annual contributions / Core earnings per share expected to increase by around 1 euro to 6.80 euros in 2019, with a target of around 10 euros in 2022 / EBITDA margin before special items set to amount to over 30 percent in 2022 / Efficiency and structural measures expected to result in the reduction of around 12,000 of 118,200 jobs worldwide, a significant number of them in Germany
Source: Bayer Company News - Category: Pharmaceuticals Source Type: news